18th Jun 2019 14:59
PRESS RELEASE
FOR IMMEDIATE RELEASE
Results of 2019 Annual General Meeting
Guildford, UK - 18 June 2019: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company focused on providing specialised services to the pharmaceutical industry, announces the results of voting on the resolutions put to shareholders at its Annual General Meeting held earlier today. Resolutions 1 to 6 were duly passed, whilst Resolutions 7 and 8 were not passed.
Resolutions 1 to 5 were passed on a show of hands. Details of proxy results were as follows:
Resolution number | Votes for | Votes against | Abstentions |
1 | 20,232,290 | 77,125 | 8,649 |
2 | 20,160,715 | 156,099 | 1,250 |
3 | 16,997,564 | Nil | 3,320,500 |
4 | 20,316,814 | Nil | 1,250 |
5 | 20,302,774 | 14,040 | 1,250 |
Details of voting results for Resolutions 6, 7 and 8 (including proxies) were as follows:
Resolution number | Votes for | Votes against | Abstentions |
6 | 27,839,992 | 10,681,500 | 1,250 |
7 | 27,683,893 | 10,837,599 | 1,250 |
8 | 27,610,768 | 10,910,724 | 1,250 |
The full text of all resolutions can be found in the Notice of Annual General Meeting on the Company's website www.ergomedplc.com
ENDS
Enquiries:
Ergomed plc | Tel: +44 (0) 1483 402 975 |
Miroslav Reljanović (Executive Chairman) | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Freddie Barnfield / Huw Jeremy (Nominated Adviser) | |
James Black (Broker) | |
Consilium Strategic Communications - for UK enquiries | Tel: +44 (0) 20 3709 5700 |
Chris Gardner / Mary-Jane Elliott | |
Matthew Neal / Olivia Manser | |
MC Services - for Continental European enquiries | Tel: +49 211 5292 5222 |
Anne Hennecke |
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
Related Shares:
ERGO.L